Combinations of three or four HIV1 virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbers

Biomedicine and Pharmacotherapy

Volumn 51, Issue 10, 1997, Pages 417-426

  Mathe G ^a   Morette, C ^a   Hallard, M ^a   Blanquet, D ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

AIDS; Drug combinations; HIV; Tritherapy; Virostatics

Indexed keywords

ACRIFLAVINE; ANTIVIRUS AGENT; DIDANOSINE; ELLIPTICINE DERIVATIVE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; N(2),N(6) DIMETHYL 9 HYDROXYELLIPTICINIUM; N(2),N(6)-DIMETHYL-9-HYDROXYELLIPTICINIUM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS LOAD; AIDS RELATED COMPLEX; ANIMAL; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; FRIEND LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; NOTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROVIRUS INFECTION; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; ANIMALS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ELLIPTICINES; FOLLOW-UP STUDIES; FRIEND MURINE LEUKEMIA VIRUS; HIV-1; HUMANS; MICE; RETROVIRIDAE INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 0031282881     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)82319-0     Document Type: Article

References (39)

1. 1-AIDS "tritherapy" failure. A challenging model. Biomed Pharmacother 1997;51:413-16
2. Cohen J. The daunting challenge of keeping HIV suppressed. Science 1997;277:32
3. Oldstone MBA. HIV versus cytotoxic T-lymphocyte - the war being lost. N Eng J Med 1997;337:1306
4. Nau JY. Les associations de lutte contre le SIDA s'inquiètent de la progression des résistances aux trithérapies. Le Monde 17 September 1997;8
5. Nau JY. Les experts préconisent une trithérapie immédiate chez les personnes infectées par le virus du SIDA. Le comité Dormont s'interroge sur la prescription des traitements en urgence. Le Monde 9 October 1997:11
6. Mathé G, Pontiggia P, Bourut C et al. In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS. Biomed Pharmacother 1994;48:51
7. Mathé G, Amiel JL, Friend Ch. Essai de traitement de la leucémie de Charlotte Friend par la greffe de cellules hématopoiétiques de donneurs isogéniques vaccinés contre le virus. Bull Cancer 1962;49:416
8. Mathé G, Amiel JL. Réduction de la concentration plasmatique du virus leucémigène de Charlotte Friend par immunothérapie adoptive (greffe de moelle osseuse allogénique). C R Acad Sci Paris 1964;259:4408
9. Ruprecht RM, Bernard LD, Ting-Chao Chou et al. Murine models for evaluating antiretroviral therapy. Cancer Res (suppl) 1990;50:5618s
10. Clarysse A, Kenis Y, Mathé G. Cancer Chemotherapy. New York: Springer, 1976
11. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/Lymphadenopathy virus-associated virus (HTLV-III/LAV) hy 2', 3-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911
12. Cameron B, Health-Chiozzi M, Kravic K et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: The Program and Abstract of the 3rd Conf on Retroviruses and Opportunistic infections. Washington DC, 1996. Abstract no LB6a
13. Salgo MB, Beattie D, Donatacci L et al. Saquinavir (Invirase, SQV) vs HIV-ID (zalcitabin, ddC) vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take ritonavir (zidovudine, ZDV. In: The Program and Abstract of the XV Intern. Conference on AIDS. Vancouver, 1996. Abstract MOB 410
14. Gulick RM, Mellors J, Havlir D et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). Take ritonavir (zidovudine, ZDV. In: The Program and Abstract of the XV Intern. Conference on AIDS. Vancouver, 1996. Abstract MOB 410
15. Executive summary dideoxyinosine/dideoxycytidine CPCRA study. In: Community Programs for Clinical Research on AIDS. Bethesda, 1993
16. th Interscience Conference on Antimicrobials Agents and Chemotherapy. San Francisco, CA; 17-20 September 1995
17. Davis RH, Williams H, Smith HJ. Intermolecular forces and stereo-specificity in drug action. In: Introduction to the Principal of Drug Design. London: Wright, 1988
18. Fosse P, René B, Le Bret M et al. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 1991;12:2868
19. Kreuzer KN, DNA topoisomerases as potential targets of antiviral action. Pharmac Ther 1989;43:177
20. Mathé G, Huppert J, Chenu E, Bourut C. Amino-acridines action on Friend's virus retrovirus in relation to their molecular ionization. Biomed Pharmacother 1989;43:235
21. Boyd ML. Treatment of early acute anterior urethrids with acriflavine. Urol Cutan Rev 1930;34:303
22. Adriapharm, eds. Pharmacopée Française. Xème ed. Paris: Maisonneuve; 1995
23. 1 infected patients. In: Sixth International Conference on AIDS. 20-24 June. San Francisco, 1990
24. Mathé G, Pontiggia P. A screening model of anti-HIV non AZT cross resistance virostatics. Biomed Pharmacother 1993;47:461
25. Mathé G, Chenu E, Bourut C et al. The in vivo effect of ellipticine analogues on the blood concentration of Friend's virus: a murine model for studying anti-HIV drugs. Biomed Pharmacother 1993;47:457
26. Paoletti C, Le Pecq JB, Dat-Xuong N et al. Antitumoractivity, pharmacology and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium. Rec Res Cancer Res 1980;74:107
27. Mathé G, Chenu E, Bourut C, Bravo-Cuellar A, Orbach-Arbouys S. The in vivo effect of ellipticine analogues on the viremia of Friend virus: a murine model for studying anti-HIV drugs. Interdisciplinary World Congress on Antimicrobial and Anticancer Drugs. Geneva, Switzerland, 30 March-1 April 1992
28. 1-AIDS complex. Biomed Pharmacother 1996;50:510
29. 1 plasma RNA precedes their appearance in proviral DNA. 2nd Intern Congress on Drug Therapy in HIV infection, Glasgow. AIDS 1994;8(suppl 4):S19
30. 1-infection. Nature 1995;373:123
31. Bonhoeffer S et al. Causes of HIV diversity. Nature 1995;376:125
32. Nowak MA. HIV mutation rate. Nature 1990;347
33. Kuritzkes DR. Development of resistances to malivudine (3TC) in NUCA 3001, a phase II comparative trial of 3TC versus 3TC+2DV. Second National Conference on Human Retroviruses and Related Infection (Abstracts). Washington, 1995
34. Kojima E, Shirasaka T, Anderson BD et al. HIV-1 viremia changes and development of drug-related mutations in patients with symptomatic human immunodeficiency virus I infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995;171:1152
35. Mathé G, Pontiggia P, Orbach-Arbouys S et al. AIDS therapy with two, three of four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. Biomed Pharmacother 1996; 50:220
36. 1 particle cure AIDS patient. II: Second part. Decrease of VL and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? Biomed Pharmacother 1996;50:473
37. Mathé G. SIDA. Paris: Editions La Coutellerie; 1995
38. Wonnacott TH, Wonnacott RJ. Statistique. Paris: Economia; 1996
39. 1-AIDS complex pathophysiology. New Directions in Blood Cells and Bone Marrow Transplant. Milwaukee, WI; September 13 1997